25I-NBOH

25I-NBOH (2C-I-NBOH, NBOH-2CI) is a derivative of the phenethylamine derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5HT2A receptor. 25I-NBOH has been sold as a drug and produces similar effects in humans to 2C-I and other psychedelic phenethylamines.

Chemistry[edit | edit source]

25I-NBOH, or 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethan-1-amine, is a phenethylamine molecule which belongs to the 25x-NBOH series of psychedelic hallucinogens. The structure of 25I-NBOH contains a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional hydroxy (OH) substitution at R2. It is a derivative of 2C-I, which is itself a derivative of mescaline.

Pharmacology[edit | edit source]

25I-NBOH's psychedelic effects are believed to come from its efficacy at the 5HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Effects[edit | edit source]

The effects of 25I-NBOH are usually compared to those of 2C-I and other psychedelic phenethylamines, and may include open and closed eye visuals, time distortion, enhanced introspection, and ego loss. Its effects can also include negative aspects such as nausea, confusion, and paranoia.

Legal Status[edit | edit source]

As of October 2015, 25I-NBOH is a controlled substance in China. It is also illegal in Sweden as of January 2016. The legal status in other countries may vary.

References[edit | edit source]

25I-NBOH Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.